

# Effects of the *PNPLA3*-SNP rs738409 on Serum Transaminase Levels are Modified by Body Mass Index and Alcohol Consumption

## Abstract

**Introduction:** The single-nucleotide polymorphism (SNP) rs738409 C>G is located in the coding region of the patatin-like phospholipase domain-containing protein 3 (*PNPLA3*). It has been shown to be strongly associated with increased serum activities of transaminase enzymes, with risk of progression to cirrhosis and with fat accumulation in the liver. The study tests whether *PNPLA3* rs738409 modifies the associations of body mass index (BMI) and alcohol consumption with serum transaminase levels (i.e., alanine transaminase (ALT) and aspartate transaminase (AST)).

**Methods:** Population-based data were drawn from two independent population-based cohorts within the Study of Health of Pomerania project (N= 8,056), conducted in Northeast Germany.

**Results:** We found several gene-environment interactions: The positive association between ALT and BMI was steeper for minor homozygotes (GG) and heterozygotes (CG) than for major homozygotes (CC) ( $p < 0.001$ ). Similarly the relationship between AST and BMI in women was stronger with each G allele ( $p = 0.006$  for CG,  $p = 0.001$  for GG); higher levels of alcohol consumption were associated with steeper increase of AST activities for heterozygous men ( $p = 0.048$ ).

**Discussion:** Results show that the SNP rs738409 modifies the associations of BMI and alcohol consumption with liver enzymes. This would have implications for guidance of patients if their genetic predisposition would be known. Heterozygous and especially minor homozygous subjects are inherently at particular high risk for liver-related problems. In addition, their risk rises even stronger in the presence of modifiable risk factors such as BMI or alcohol consumption.

**Keywords:** Gene-environment interactions; Study of Health in Pomerania

## Research Article

Volume 1 Issue 1 - 2017

**Meffert PJ<sup>1\*</sup>, Kühn JP<sup>2,5</sup>, Baumeister SE<sup>1,6</sup>, Lerch MM<sup>3</sup>, Mayerle J<sup>3,4</sup> and Völzke H<sup>1</sup>**

<sup>1</sup>Institute for Community Medicine, Ernst Moritz Arndt University of Greifswald, Germany

<sup>2</sup>Department of Medicine A, Ernst Moritz Arndt University of Greifswald, Germany

<sup>3</sup>Department of Diagnostic Radiology and Neuroradiology, University of Greifswald, Germany

<sup>4</sup>Department of Medicine, Ludwig-Maximilians-University, Germany

<sup>5</sup>Institut und Poliklinik für Röntgendiagnostik, Carl-Gustav Carus University, Germany

<sup>6</sup>Department of Epidemiology and Preventive Medicine, University of Regensburg, Germany

**\*Corresponding author:** Peter J Meffert, Institute for Community Medicine, Ernst Moritz Arndt University of Greifswald, Walther-Rathenau-Str48, D-17475 Greifswald, Germany, Tel: ++49 39973 710016; Email: p.j.meffert@web.de

**Received:** July 21, 2017 | **Published:** September 21, 2017

**Abbreviations:** SNP: Single-Nucleotide Polymorphism; ALT: Alanine Transaminase; AST: Aspartate Transaminase; GG: Minor Homozygotes; CG: Heterozygotes; CC: Major Homozygotes; BMI: Body Mass Index; NAFLD: Non-Alcoholic Fatty Liver Disease; SHIP: Study Of Health In Pomerania

## Introduction

For the common rs738409 C>G SNP, which is located in the patatin-like phospholipase domain-containing protein 3 (*PNPLA3*), a strong association between non-alcoholic fatty liver disease (NAFLD) has been detected [1], approved [2-8] and expanded to an association with liver-fat content in general [8-13] and serum transaminase levels [14]. Also an association to a higher risk of progression to cirrhosis in NAFLD patients has been shown [15]. Transaminase levels, particularly of alanine transaminase (ALT) and aspartate transaminase (AST), are strong indicators of hepatic steatosis [16] as well as of cardio-metabolic risks [17] and are associated with mortality even within their reference ranges [18]. Yet, a small number of studies reported gene-environment

interactions for rs738409. Recently it has been shown that the G allele of rs738409 is associated with lower serum triglyceride and cholesterol levels and higher ALT levels in overweight individuals only [19]. Children with the minor G allele had more liver fat per unit omega-fat intake than major homozygous children [20]. In another study, sugar and carbohydrate intake in Hispanic children was positively related to hepatic fat fraction in GG carriers but not in CG and CC carriers [21].

Because both the genetic variant and environmental conditions such as physical activity or obesity influence serum-transaminase levels [22], we consider them as a valuable model for the examination of gene-environment interactions. We chose body mass index (BMI) and alcohol consumption as common environmental factors because they are tightly associated with liver-enzyme activity [23], liver-fat content, hepatic steatosis and increased risk of liver fibrosis and cirrhosis [24]. Further, they may accelerate insulin resistance and cardiovascular diseases [25] and are therefore highly relevant for health care. In addition, BMI and alcohol consumption can be in general modified by changing the

individual's life style. Regarding the consequences of different genetic makeups, physicians and patients would like to know: Is the genetic risk associated with patient-related factors that can be influenced by medical treatment or behavioural changes? The study tests whether *PNPLA3* rs738409 modifies the associations of BMI and alcohol consumption with serum transaminase levels (i.e., ALT, AST).

## Methods

### Population and study design

To investigate the relationship between rs738409, transaminase levels, BMI and alcohol consumption, we used data from the baseline Study of Health in Pomerania (SHIP) [26,27]. The study population consists of adult Caucasian residents of Western Pomerania in Northeast Germany. From the total population of West Pomerania comprising 213,057 inhabitants in 1996, a two-stage stratified random cluster sample of adults aged 20-79 years was drawn (for further details see [26]). The net sample comprised 6265 eligible subjects. Of these, 4308 subjects (n= 2192 women; response of 68.8%) participated in the SHIP-0 between 1997 and 2001. A separate stratified random sample of 8016 adults aged 20-79 years was drawn for the SHIP-TREND cohort between 2008 and 2011 of which 4420 participated (N= 2274 women, response of 55.1%). We pooled both cohorts for this analysis.

Out of the 8728 SHIP subjects, genotypes were missing in 375 (4.3%) of the individuals due to insufficient imputation quality (call rate < 86 %). Missing genotype information was not significantly associated with and ALT and AST activities (logistic regression, adjusted for age and sex, with missing status as outcome,  $p= 0.096$ ,  $N= 8689$  and  $p= 0.610$ ,  $N= 8694$ , respectively). For another 297 individuals (3.4%) covariates were missing, in 255 datasets concerning alcohol consumption. Thus, the analytic sample comprised 8056 participants aged 20-83 years (N= 4134 women). Approval was obtained by the local ethic committee, and informed consent was given by all participants.

### Genotyping and imputation

DNA samples of were genotyped using the Affymetrix Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA), genotypes were determined using Birdseed2 clustering algorithm [27]. Imputation of the SNP rs738409 was performed with the software IMPUTE against HapMap II CEU. Details of the genotyping and imputation are reported elsewhere [28]. Instead of the raw imputed values, we used rounded values from the imputed SNP (0,1,2). Thus we used genotype as a categorical variable resulting in a codominant genetic model that is most powerful to detect associations when the inheritance model is not known [29]. Arrays with a QC-call rate < 86% were excluded. The final call rate for genotyping was > 0.99 for the SHIP-0 and > 0.92 for the SHIP-TREND. Genetic data were stored using the database Cache (InterSystems, Cambridge, MA, USA).

### Data collection

Data were gathered by trained and certified medical staff. Self-reported alcohol consumption was assessed using a beverage-

specific quantity-frequency measure [30]: number of days with alcohol consumption (beer, wine, spirits) and average daily alcohol consumption for such a day over the past month. Average alcohol consumption (in grams per day) was calculated by multiplying frequency and amount of alcohol from beer, wine and spirits, respectively, using a standard ethanol content of 4.8 percent (by volume) in beer, 11 percent in wine, and 33 percent in spirits to conversion [31]. BMI was calculated as  $\text{kg/m}^2$ . Non-fasting blood samples were drawn from the cubital vein in the supine position. Serum ALT and AST were measured photometrically at 37 °C (Hitachi 717 and 704, Roche, Mannheim, Germany). Further details on the study protocol can be found in [28].

### Statistical Analyses

We applied ordinary least-square linear regression; since the relationships between liver enzymes and covariates were expected to be non-linear, we transformed the independent variables if appropriate to get a linear relationship [32]. We modelled gene-environment interactions with the STATA program 'mfpigen' with an alpha level for interactions of 0.05 [33,34]. The polynomial to be fit was restricted to two degrees to avoid overfitting. Since variances were heteroscedastic, we applied robust standard errors. Models were adjusted for age and sex, an approach suitable in population-based studies [35]. Statistical analyses were performed using STATA 13.0 (Stata Corp., College Station, TX, USA). For the display of the interaction effects we used predictive margins with age fixed at 50 years and 50% females for the unisex model.

In higher ranges of alcohol consumption data were very sparse. We therefore restricted the analyses to the range with sufficient data and eliminated for these analyses datasets with more than 60 g alcohol per day in women (N= 6) and more than 130 g in men (N= 4), additionally with more than 13 g in minor homozygous women (N= 15) and with more than 60 g in minor homozygous men (N= 7).

For models examining gene-environment interactions also interactions with all covariates should be included to regard effect modifications of possible confounders [36]. For example, if we model an interaction effect between alcohol consumption and a genetic group, adjusting for age and sex, a model should include also the interactions genetic group  $\times$  age and genetic group  $\times$  sex. However, since we considered a confounding effect of age and sex as unlikely, we conducted the main analyses without these interaction terms. As a sensitivity analysis we included all interactions between covariates and SNP in the models which did not considerably change the results.

## Results

In our study population of 8056 individuals, 60.4% were major homozygous (CC), 34.7% heterozygous (CG) and 4.9% minor homozygous (GG; Table 1). Age and sex did not significantly differ among genetic groups ( $p= 0.33$  and  $p= 0.12$ , respectively) with a slightly higher proportion of women in the minor homozygous group (55.0% compared to overall 51.3%). Carriers of the G allele of *PNPLA3* rs73809 did not significantly differ regarding BMI ( $p = 0.887$ ) and alcohol consumption ( $p= 0.298$ ) but had increased liver enzymes compared to CC subjects ( $p < 0.001$ , Table 1).

**Table 1:** Characteristics of the study population.

Characteristic	Variant of rs738409			p value
	CC	CG	GG	
rs738409 (%)	4865 (60.4%)	2798 (34.7%)	393 (4.9%)	
Age (years) adj for sex	50.9 (15.8)	50.4 (16.0)	51.3 (15.5)	0.328
Female sex (%) adj for age	2457 (50.5%)	1461 (52.2%)	216 (55.0%)	0.123
Body Mass Index (kg/m <sup>2</sup> )	28.3 (28.13, 28.47)	28.24 (28.03, 28.46)	28.25 (27.76, 28.74)	0.887
Alcohol Consumption (g/d)	11.8 (11.2, 12.3)	11.9 (11.2, 12.5)	10.7 (9.3, 12.1)	0.298
Alanine Transaminase (μmol · sl <sup>-1</sup> )	0.491 (0.480, 0.501)	0.532 (0.517, 0.547)	0.607 (0.567, 0.646)	< 0.001
Aspartate Transaminase (μmol · sl <sup>-1</sup> )	0.349 (0.343, 0.356)	0.372 (0.362, 0.383)	0.419 (0.390, 0.447)	< 0.001

Age is given as marginal mean (standard deviation) adjusted for sex with 50% women; rs738409 is given as numbers (%); sex is given as marginal mean adjusted for age; body mass index, liver enzymes and alcohol consumption are given as mariginal means (95% confidence interval) fixed at an age of 50 years and 50% women; p values refer to a combined test over all three genotypes.

Relationship of BMI and alcohol consumption with transaminase levels were modified by *PNPLA3* rs73809. The association between of BMI and ALT got stronger with each additional G allele ( $p < 0.001$ , Table 2, Figure 1A). For all other relationships, a significant interaction with sex was detected (at least one of CG or GG with a p value  $< 0.05$  for the three-fold interaction SNP × sex × alcohol, not shown). Consequently, further analyses were conducted separately for men and women. There was no significant interaction between the SNP and alcohol

consumption with ALT used as outcome (Table 2). Regarding AST and BMI, there was no significant interaction in men ( $p = 0.737$  for CG,  $p = 0.197$  for GG) but in women ( $p = 0.006$  for CG,  $p = 0.001$  for GG, Table 3, Figure 1B). In men, higher levels of alcohol consumption were associated with slightly higher AST values for each G allele, being significant for GC ( $p = 0.048$  for CG,  $p = 0.386$  for GG, Table 4, Figure 1). In women, there was no significant interaction between the genetic variant and alcohol consumption ( $p = 0.338$  for CG,  $p = 0.121$  for GG, Table 4).

**Table 2:** Results from regression with ALT as outcome and interaction between body mass index/alcohol consumption and rs738409.

	Coefficient	p value	95% confidence interval	
Men and women (N = 8056, R <sup>2</sup> = 0.167)				
rs738409				
CC	Reference			
GC	0.0471	< 0.001	0.0318	0.0625
GG	0.1323	< 0.001	0.0927	0.1718
BMI (kg/m <sup>2</sup> ; Polynomial: BMI <sup>-1</sup> )	-1.075	< 0.001	-1.195	-0.9551
Age (Years; Polynomial: age <sup>3</sup> )	-0.0004	< 0.001	-0.0004	-0.0003
Sex (Female)	-0.1776	< 0.001	-0.1906	-0.1647
rs738409 x BMI				
CC	Reference			
GC	-0.3663	< 0.001	-0.5661	-0.1665
GG	-1.1166	< 0.001	-1.6412	-0.5921
Men only (N = 3914, R <sup>2</sup> = 0.070)				
rs738409				
CC	Reference			
GC	0.0613	< 0.001	0.0359	0.0867

GG	0.1702	< 0.001	0.1035	0.2369
Alcohol Consumption (g/day)	0.0019	< 0.001	0.0011	0.0027
Age (years)	-0.0005	< 0.001	-0.0006	-0.0004
rs738409 x alcohol				
CC	Reference			
GC	0.001	0.196	-0.0005	0.0025
GG	0.0031	0.193	-0.0016	0.0077
Women only (N= 4119, R <sup>2</sup> = 0.030)				
rs738409				
CC	Reference			
GC	0.0145	0.053	-0.0016	0.0291
GG	0.0693	< 0.001	0.0304	0.1083
Alcohol Consumption (g/day)	0.0008	0.46	-0.0013	0.003
Age (years; polynomial: age <sup>0.5</sup> )	-0.4097	< 0.001	-0.485	-0.3344
rs738409 x alcohol				
CC	Reference			
GC	-0.0013	0.357	-0.004	0.0014
GG	-0.0099	0.184	-0.0245	0.0047


**Table 3:** Results from regression with AST as outcome and interaction between body mass index and rs738409.

	Coefficient	p value	95% confidence interval	
Men only (N = 3922, R <sup>2</sup> = 0.032)				
rs738409				
CC	Reference			
GC	0.0404	< 0.001	0.0221	0.0587
GG	0.0878	< 0.001	0.044	0.1317
BMI (kg/m <sup>2</sup> )	0.0047	< 0.001	0.0027	0.0067
Age (years; Polynomial 1: age <sup>0.5</sup> )	0.6491	< 0.001	0.446	0.8522
Age (years; Polynomial 2: age)	-0.1579	< 0.001	-0.2039	-0.1119
rs738409 x BMI				
CC	Reference			
GC	0.0006	0.737	-0.003	0.0043
GG	0.0135	0.197	-0.007	0.034
Women only (N = 4134, R <sup>2</sup> = 0.048)				
rs738409				

CC	Reference			
GC	0.0063	0.17	-0.0027	0.0153
GG	0.051	0.003	0.0173	0.0847
BMI (kg/m <sup>2</sup> )	0.0007	0.29	-0.0006	0.0019
Age (years; Polynomial: age <sup>3</sup> )	0.0013	< 0.001	0.001	0.0016
rs738409 x BMI				
CC	Reference			
GC	0.0027	0.006	0.0008	0.0046
GG	0.0118	0.001	0.0046	0.0191

**Table 4:** Results from regression with AST as outcome and interaction between alcohol consumption and rs738409.

	Coefficient	p value	95% confidence interval	
<b>Men only (N = 3914, R<sup>2</sup> = 0.050)</b>				
rs738409				
CC	Reference			
GC	0.0375	< 0.001	0.0196	0.0554
GG	0.0968	0.001	0.0401	0.1534
Alcohol consumption (g/day)	0.0023	< 0.001	0.0017	0.0028
Age (years)	-0.0002	0.289	-0.0007	0.0002
rs738409 x alcohol				
CC	Reference			
GC	0.0012	0.048	0.00001	0.0024
GG	0.0027	0.386	-0.0034	0.0089
<b>Women only (N = 4107, R<sup>2</sup> = 0.043)</b>				
rs738409				
CC	Reference			
GC	0.0081	0.08	-0.001	0.0171
GG	0.0586	0.002	0.0207	0.0966
Alcohol Consumption (g/day, Polynomial: Alcohol <sup>3</sup> )	0.0017	0.086	-0.0002	0.0036
Age (Years)	0.0016	0	0.0014	0.0019
rs738409 x alcohol				
CC	Reference			
GC	-0.001	0.338	-0.0029	0.001
GG	-0.013	0.121	-0.0293	0.0034



**Figure 1:** Predictive margins between liver-enzyme activities and environmental factors body mass index (BMI) and alcohol consumption by genetic group, adjusted for age (all models) and sex (first model, panel A); ALT: Alanine Transaminase; AST: Aspartate Transaminase.

## Discussion

We found interactions between *PNPLA3* rs73809 and BMI and alcohol consumption, respectively, that together influenced liver enzyme levels. The increase in ALT levels was steeper for each G allele in BMI (Figure 1A), similarly for AST in women (Figure 1B) and AST and alcohol in men (Figure 1C). In all cases, effect sizes of GG on BMI and alcohol were more than twice as high as for CG (on average about fourfold), indicating a more than additive effect of the G alleles. Our results further show that there are sex-specific differences in SNP-related transaminase levels: The increase in transaminase levels per G allele is much steeper in men compared to women, about fivefold for CG and twofold for GG. This implies that, besides the effect of gene-environment interactions, women seem to be at lower risk for increased transaminase levels when carrying a G allele.

In line with our findings previous studies also found not significant differences in BMI between the genetic groups [37,38]. Several studies report an association of the G allele of rs738409 with alcoholic liver disease and alcoholic cirrhosis [39-42]. This finding is supported for men by our results; however, previous studies did not explicitly examine sex-specific differences for this association and examined mainly male alcoholics. Regarding gene-environment interactions, dietary issues matter as well in children [20,21] as in adults for which it has been reported that with higher consumption of sucrose the increase in serum triglycerides was higher with each G allele [19]. For ALT we confirmed previous findings [19] that there are only differences in ALT levels between the genetic groups in overweight individuals.

Our findings illustrate that gene-environment interactions may contribute to the heritability of liver-related problems. If these will be confirmed in further validation studies, this would suggest some implications for patients and clinicians. A physician who has genetic information on rs738409 available for a patient, he or she may warn patients with a G allele to be particularly cautious because their transaminase levels increase stronger with increasing BMI or alcohol consumption compared to CC individuals

## Acknowledgement

The SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, 01ZZ0403 and 03IS2061A), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. We also thank Mr. Alexander Teumer for valuable contributions that improved the initial manuscript.

## References

1. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. (2008) Genetic variation in *PNPLA3* confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 40(12): 1461-1465.
2. Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, et al. (2009) Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. *Diabetes* 58(11): 2616-2623.

3. Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, et al. (2010) Association of the rs738409 polymorphism in *PNPLA3* with liver damage and the development of nonalcoholic fatty liver disease. *BMC Med Genet* 11: 1471-2350.
4. Wagenknecht LE, Palmer ND, Bowden DW, Rotter JJ, Norris JM, et al. (2011) Association of *PNPLA3* with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. *Liver Int* 31(3): 412-416.
5. Speliotes EK, Butler JL, Palmer CD, Voight BF, Giant Consortium, et al. (2010) *PNPLA3* variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. *Hepatology* 52(3): 904-912.
6. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, et al. (2011) A common variant in the *PNPLA3* gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. *J Pediatr* 158(5): 740-744.
7. Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (*PNPLA3*) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology* 53(6): 1883-1894.
8. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, et al. (2010) I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. *Hepatology* 52(4): 1274-1280.
9. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, et al. (2009) A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. *J Lipid Res* 50(10): 2111-2116.
10. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, et al. (2010) Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology* 51(4): 1209-1217.
11. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, et al. (2010) The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (*PNPLA3*) with histological severity of nonalcoholic fatty liver disease. *Hepatology* 52: 894-903.
12. Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, et al. (2010) Specifically *PNPLA3*-mediated accumulation of liver fat in obese patients with type 2 diabetes. *J Clin Endocrinol Metab* 95(12): E430-E436.
13. Hyysalo J, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, et al. (2012) Genetic variation in *PNPLA3* but not *APOC3* influences liver fat in non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 27(5): 951-956.
14. Valenti L, Maggioni P, Piperno A, Rametta R, Pelucchi S, et al. (2012) Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. *World J Gastroenterol* 18(22): 2813-2820.
15. Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, et al. (2016) The *PNPLA3* rs738409 C>G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. *Scandinavian journal of gastroenterology* 51(8): 967-973.
16. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, et al. (2006) Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. *Diabetes Metab Res Rev* 22(6): 437-443.
17. Targher G, Arcaro G (2007) Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. *Atherosclerosis* 191(2): 235-240.
18. Hyeon CK, Chung MN, Sun HJ, Han KH, Oh DK, et al. (2004) Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. *BMJ* 328(7446): 983.
19. Stojkovic IA, Ericson U, Rukh G, Riddestråle M, Romeo S, et al. (2014) The *PNPLA3* Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels. *Genes Nutr* 9(2): 388.
20. Santoro N, Savoye M, Kim G, Marotto K, Shaw MM, et al. (2012) Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the *PNPLA3* gene and the dietary omega6/omega3 PUFA intake. *PLoS One* 7(5): e37827.
21. Davis JN, Le KA, Walker RW, Vikman S, Spruijt-Metz D, et al. (2010) Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in *PNPLA3* and high dietary carbohydrate and sugar consumption. *Am J Clin Nutr* 92(6): 1522-1527.
22. Lee YS, Kek BL, Poh LK, Saw SM, Loke KY (2008) Association of raised liver transaminases with physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese children. *J Pediatr Gastroenterol Nutr* 47(2): 172-178.
23. Salvaggio A, Periti M, Miano L, Tavanelli M, Marzorati D (1991) Body mass index and liver enzyme activity in serum. *Clin Chem* 37(5): 720-723.
24. Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C (2004) Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies. *Hepatology* 40(4): 820-826.
25. Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med* 363(14): 1341-1350.
26. John U, Greiner B, Hensel E, Lüdemann J, Piek M, et al. (2001) Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. *Soz Präventivmed* 46(3): 186-194.
27. Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemes J, et al. (2008) Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. *Nat Genet* 40(10): 1253-1260.
28. Völzke H, Alte D, Schmidt CO, Radke D, Lohrbein R, et al. (2011) Cohort Profile: The Study of Health in Pomerania. *Int J Epidemiol* 40(2): 294-307.
29. Lettre G, Lange C, Hirschhorn JN (2007) Genetic model testing and statistical power in population-based association studies of quantitative traits. *Genet Epidemiol* 31(4): 358-362.
30. Baumeister SE, Alte D, Meyer C, John U (2005) [Health Risk drinking and problematic consumption of alcohol in Pomerania: comparative analysis of the Study of Health in Pomerania (SHIP) compared with the Federal German Health and Examination Survey in 1998]. *Gesundheitswesen* 67(1): 39-47.
31. Buhringer G, Testing CBT (2000) Mechanisms of action: humans behave in a more complex way than our treatment studies would predict!. *Addiction* 95(11): 1715-1716.
32. Sauerbrei W, Royston P (1999) Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. *J R Stat Soc: Series A* 162(1): 71-94.
33. Royston P (2012) *MFPIGEN*: Stata module for modelling and displaying interactions between continuous predictors. *Statistical Software Components*.

34. Sauerbrei W, Royston P (2010) Modelling interactions with continuous variables. *Gesundheitswesen* 72: V208.
35. Pirinen M, Donnelly P, Spencer CC (2012) Including known covariates can reduce power to detect genetic effects in case-control studies. *Nat Genet* 44(8): 848-851.
36. Keller MC (2014) Gene x environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. *Biol Psychiatry* 75(1): 18-24.
37. Johansson LE, Lindblad U, Larsson CA, Råstam L, Ridderstråle M (2008) Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. *Eur J Endocrinol* 159(5): 577-583.
38. Palmer CN, Maglio C, Pirazzi C, Burza MA, Adiels M, et al. (2012) Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the *PNPLA3* 148M variant. *PLoS One* 7(6): e39362.
39. Tian C, Stokowski RP, Kershenovich D, Ballinger DG, Hinds DA (2010) Variant in *PNPLA3* is associated with alcoholic liver disease. *Nat Genet* 42(1): 21-23.
40. Stickel F, Hampe J (2012) Genetic determinants of alcoholic liver disease. *Gut* 61(1): 150-159.
41. Stickel F, Buch S, Lau K, Meyer zu Schwabedissen H, Berg T, et al. (2011) Genetic variation in the *PNPLA3* gene is associated with alcoholic liver injury in caucasians. *Hepatology* 53(1): 86-95.
42. Trepo E, Gustot T, Degre D, Lemmers A, Verset L, et al. (2011) Common polymorphism in the *PNPLA3*/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. *J Hepatol* 55(4): 906-912.